CMPX - Compass Therapeutics Inc. logo

Compass Therapeutics Inc.

CMPX

Compass Therapeutics develops antibody-based therapeutics targeting cancer, focusing on angiogenesis and immune response. Its pipeline includes bispecific antibodies and monoclonal antibodies aimed at enhancing anti-tumor activity and overcoming immune evasion.

โš•๏ธ Healthcare NASDAQ Listed 2021 $ USD
$1,000 invested 30 years ago โ†’$318today

Score Overview

1 Year
Scoreโ€”
Net Growth-10.46%
Net TrendShrank
Net Income Consistencyโ€”
Rev Growthโ€”
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Scoreโ€”
Net Growth10.63%
Net Trend20%
Net Income Consistencyโ€”
Rev Growthโ€”
Rev Trend20%
Revenue Consistencyโ€”
All Time
Scoreโ€”
Net Growth10.63%
Net Trend20%
Net Income Consistency
Rev Growthโ€”
Rev Trend20%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Compass Therapeutics Inc. has ranked, year by year

Measure
Fundamentals Window

Not enough ranking history to display a chart

This chart needs at least two years of available HDB Score rankings on 10 years of fundamentals. CMPX does not have enough ranked years in the public Archive through 2021.

More recent Archive years are available with Membership. Coverage varies by company and measure.

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-10-09
$ 0.99โ€”
1 Year2025-10-09
$ 4.07-75.60%
5 Years2021-10-08
$ 3.40-70.79%
10 Years2006-02-24
$ 8.36-88.12%
20 Years2006-02-24
$ 8.36-88.12%
30 Years1996-10-09
$ 3.13-68.22%
All Time2021-04-05
$ 8.50-88.32%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 0.00-$ 73M$ 179M
2025$ 0.00-$ 66M$ 208M
2024$ 850K-$ 49M$ 126M
2023$ 0.00-$ 42M$ 152M
2022$ 0.00-$ 39M$ 186M
IPO2021$ 0.00-$ 82M$ 144M
CMPX - Compass Therapeutics Inc. logo

Compass Therapeutics Inc. fundamental performance

Across Compass Therapeutics Inc.'s full reported history, from 2021 to 2025, revenue held from $ 0.00 to $ 0.00 and net income went from -$ 82M to -$ 66M. Revenue increased in 20% of the years measured; net income in 20%.

Membership

Explore CMPX with current data

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 5,126 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies